×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DERM – journey medical corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DERM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/9
10:00 am
derm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
4/2
01:03 pm
derm
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Low
Report
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/29
09:28 pm
derm
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks [Yahoo! Finance]
Medium
Report
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks [Yahoo! Finance]
3/26
08:02 pm
derm
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]
Medium
Report
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]
3/26
08:02 am
derm
Journey Medical (DERM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $13.00 price target on the stock.
High
Report
Journey Medical (DERM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $13.00 price target on the stock.
3/25
11:23 pm
derm
Journey Medical Corp (DERM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
High
Report
Journey Medical Corp (DERM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
3/25
10:47 pm
derm
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/25
04:01 pm
derm
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
High
Report
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Date
Time
Symbol
Company Name
Action
%Chg
3/25/2026
04:01 pm
derm
journey medical corporation
BEAT
Report
-30.0%
journey medical corporation
11/12/2025
04:01 pm
derm
journey medical corporation
BEAT
Report
-13.3%
journey medical corporation
8/12/2025
04:01 pm
derm
journey medical corporation
BEAT
Report
-16.6%
journey medical corporation
5/14/2025
04:01 pm
derm
journey medical corporation
BEAT
Report
18.9%
journey medical corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/6
05:55 pm
derm
Form SCHEDULE 13G/A Journey Medical Corp Filed by: WASATCH ADVISORS LP
Low
Report
Form SCHEDULE 13G/A Journey Medical Corp Filed by: WASATCH ADVISORS LP
3/26
06:00 am
derm
Form 10-K Journey Medical Corp For: Dec 31
High
Report
Form 10-K Journey Medical Corp For: Dec 31
3/25
04:05 pm
derm
Form 8-K Journey Medical Corp For: Mar 25
High
Report
Form 8-K Journey Medical Corp For: Mar 25
1/23
04:06 pm
derm
Form 424B3 Journey Medical Corp
Low
Report
Form 424B3 Journey Medical Corp
1/23
04:06 pm
derm
Form 424B3 Journey Medical Corp
Low
Report
Form 424B3 Journey Medical Corp
1/22
06:03 am
derm
Form EFFECT Journey Medical Corp
Medium
Report
Form EFFECT Journey Medical Corp
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/17
Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference
25.8%
12/10 Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15.2%
5/7 Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.0%
12/12 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.6%
8/7 Q2/2019 6/30/2019 EPS -0.330 ZacksConsensus -0.900 ActVsEst 0.570 - Beat 10.6%
6/6 Form 4 Dermira, Inc. For: Jun 04 Filed by: Cohen David E 7.3%
12/10 Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis 7.2%
6/14 Form 4 Dermira, Inc. For: Jun 12 Filed by: Nunn Jason Raleigh 5.1%
8/17 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.1%
1/3 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.1%
12/10 Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 15.2%
5/7 Dermira, Inc. (DERM) CEO Tom Wiggans on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 12.0%
12/12 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 10.6%
8/7 Q2/2019 6/30/2019 EPS -0.330 ZacksConsensus -0.900 ActVsEst 0.570 - Beat 10.6%
6/6 Form 4 Dermira, Inc. For: Jun 04 Filed by: Cohen David E 7.3%
12/10 Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis 7.2%
6/14 Form 4 Dermira, Inc. For: Jun 12 Filed by: Nunn Jason Raleigh 5.1%
8/17 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.1%
1/3 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.1%
TOP News Decliners
11/5
Form 10-Q Dermira, Inc. For: Sep 30
-9.1%
11/13 Dermira Elects Halley E. Gilbert to its Board of Directors -6.9%
6/10 Form 8-K Dermira, Inc. For: Jun 04 -6.1%
11/5 Dermira Inc (NASDAQ: DERM) had its "outperform" rating re-affirmed by analysts at Leerink Swann. They now have a $15.00 price target on the stock, down previously from $23.00. -5.6%
5/8 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
10/12 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.2%
8/7 Form 8-K Dermira, Inc. For: Aug 07 -5.0%
5/14 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.5%
8/9 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -4.4%
10/9 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis -4.1%
11/13 Dermira Elects Halley E. Gilbert to its Board of Directors -6.9%
6/10 Form 8-K Dermira, Inc. For: Jun 04 -6.1%
11/5 Dermira Inc (NASDAQ: DERM) had its "outperform" rating re-affirmed by analysts at Leerink Swann. They now have a $15.00 price target on the stock, down previously from $23.00. -5.6%
5/8 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%
10/12 Dermira Inc (NASDAQ: DERM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -5.2%
8/7 Form 8-K Dermira, Inc. For: Aug 07 -5.0%
5/14 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.5%
8/9 Dermira Inc (NASDAQ: DERM) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -4.4%
10/9 Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: